SINOMAB

SinoMab BioScience Limited
中國抗體製藥有限公司
(Incorporated in Hong Kong with limited liability)
(Stock code: 3681)

SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO 2025 ANNUAL REPORT

Reference is made to the annual report of SinoMab BioScience Limited published on 27 April 2026 (the "**2025 Annual Report**"). Unless otherwise specified, capitalized terms used in this announcement shall have the same meanings as those defined in the 2025 Annual Report.

This announcement provides supplemental information for the 2025 Annual Report and should be read in conjunction with the 2025 Annual Report.

1. USE OF PROCEEDS FROM THE 2025 SHARE SUBSCRIPTIONS

2025 Share Subscriptions

As disclosed in the 2025 Annual Report, during the Reporting Period, the Company conducted two fund raising activities by subscriptions of new shares under general mandate, including 2025 May Share Subscriptions and 2025 July Share Subscriptions.

In addition, the Company would like to provide the following supplemental information that, during the Reporting Period:—

- the net proceeds from the 2025 May Share Subscriptions were used according to the intentions previously disclosed in the Company's announcements dated 13 May 2025 and 15 August 2025; and
- the net proceeds from the 2025 July Share Subscriptions were used according to the intentions previously disclosed in the Company's announcements dated 22 July 2025, 15 August 2025 and 23 March 2026.

For further details of the use of the net proceeds raised from the 2025 May Share Subscriptions and the 2025 July Share Subscriptions, please see pages 58 to 61 of the 2025 Annual Report.

2. SHARE INCENTIVES

Share Award Scheme

As disclosed in the section headed "Share Award Scheme" in the 2025 Annual Report (pages 72 to 73 of the 2025 Annual Report), during the Reporting Period, 1,220,000 of the Awards granted under the Share Award Scheme were vested. The Company would like to clarify that such 1,220,000 Awards vested during the Reporting Period were classified as share options pursuant to the relevant accounting standard, and were disclosed accordingly under note 25(a)(ii) to the financial statements set out on page 141 of the 2025 Annual Report. As stated on pages 72 to 73 of the 2025 Annual Report, among these 1,220,000 Awards vested, 85,000 of them were exercised during the Reporting Period with a purchase price of HK$1.12. The Company would like to supplement that the weighted average closing price per Share as quoted on the Stock Exchange immediately before the date on which such 85,000 Awards were exercised was HK$1.69.

Save as disclosed above, all the other information and contents in the 2025 Annual Report remain unchanged. The information contained in this announcement does not affect the other information contained in the 2025 Annual Report and should be read in conjunction with the 2025 Annual Report.

By Order of the Board
SinoMab BioScience Limited
Dr. Shui On LEUNG
Executive Director, Chairman and Chief Executive Officer

Hong Kong, 18 September 2026

As at the date of this announcement, the executive director of the Company is Dr. Shui On LEUNG, the non-executive directors of the Company are Ms. Xiaosu WANG, Ms. Lei XUE and Dr. Jianmin ZHANG, and the independent non-executive directors of the Company are Mr. George William Hunter CAUTHERLEY, Mr. Ping Cho Terence HON, Dr. Chi Ming LEE, Ms. Chi Sau Giselle LEE and Mr. Nan SHEN.